Related Experiment Video

Updated: May 27, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Beyond taxanes: the next generation of microtubule-targeting agents

Javier Cortes1, Maria Vidal

  • 1Breast Cancer Program, Department of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron 119-129, Barcelona, Spain. jacortes@vhio.net

Breast Cancer Research and Treatment
|November 25, 2011
PubMed

Insights

New microtubule-targeting agents offer hope for metastatic breast cancer (MBC) patients resistant to standard taxane therapies. Ixabepilone and eribulin demonstrate efficacy in heavily pretreated patients, expanding treatment options.

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Therapeutics

Background:

  • Taxanes are a cornerstone of first-line treatment for metastatic breast cancer (MBC).
  • Primary or acquired resistance to taxanes limits their long-term efficacy in MBC.
  • There is a critical need for alternative therapeutic strategies to overcome taxane resistance.

Purpose of the Study:

  • To review novel microtubule-targeting agents as alternatives for MBC treatment.
  • To evaluate the clinical benefits of these agents in taxane-resistant or refractory disease.
  • To identify potential new regimens for patients progressing on standard anthracycline/taxane therapies.

Main Methods:

  • Literature review of clinical data from PubMed and congress abstract databases.
  • Analysis of efficacy and safety data for ixabepilone and eribulin in MBC.
  • Exploration of investigational microtubule-targeting agents for potential therapeutic use.

Main Results:

  • Ixabepilone, an FDA-approved microtubule stabilizer, shows efficacy in taxane-resistant MBC, improving progression-free survival when combined with capecitabine.
  • Eribulin, approved by FDA and EMA, demonstrated extended overall survival in heavily pretreated MBC patients compared to physician's choice.
  • Several investigational agents show promise for future MBC treatment strategies.

Conclusions:

  • Novel microtubule-targeting agents like ixabepilone and eribulin provide valuable options for MBC patients with taxane resistance.
  • These agents address an unmet need for effective therapies in patients who have progressed on standard chemotherapy.
  • Continued development of microtubule-targeting agents is crucial for improving outcomes in advanced breast cancer.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...